GlaxoSmithKline, a research-based pharmaceutical and healthcare company, has named Siemens as a strategic partner of the company in manufacturing automation.
The new agreement, which extends a long-standing relationship between the two companies, makes Siemens GSK’s preferred automation supplier for its production and R&D sites worldwide.
The German engineering firm said that the new partnership centers on process control, equipment control and building management systems within the manufacturing and R&D pilot plants of GlaxoSmithKline. The four main areas of focus are Modular Manufacturing, Batch Sterile Facility Blue Print, Machine and Production Line Optimization and Manufacturing Blue Print for different Dosage forms.
“Integrated automation and digitalization solutions are important levers for pharmaceutical companies to raise efficiency and productivity whilst ensuring safety and quality,” commented Eckard Eberle, CEO of Siemens’s Process Automation business unit.
Siemens will provide GSK with hardware, software and services across the entire plant life cycle, Eberle explained.
Dave Tudor, vice president of Primary Supply and leader of the Global Automation Steering Team of GSK, said: “One of our objectives is to simplify and standardize the automation space by identifying a small number of systems and suppliers and this is the first step on our journey to achieving this.”
GSK expects the partnership with Siemens to create long-term value for the company and its customers, Tudor added.
